nodes	percent_of_prediction	percent_of_DWPC	metapath
Atazanavir—ABCB1—peripheral nervous system neoplasm	0.317	1	CbGaD
Atazanavir—ABCC1—Dactinomycin—peripheral nervous system neoplasm	0.084	0.171	CbGbCtD
Atazanavir—ABCC1—Epirubicin—peripheral nervous system neoplasm	0.0608	0.124	CbGbCtD
Atazanavir—ABCC1—Vincristine—peripheral nervous system neoplasm	0.0517	0.105	CbGbCtD
Atazanavir—ABCC1—Etoposide—peripheral nervous system neoplasm	0.0474	0.0965	CbGbCtD
Atazanavir—ABCC1—Doxorubicin—peripheral nervous system neoplasm	0.0323	0.0658	CbGbCtD
Atazanavir—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0292	0.0595	CbGbCtD
Atazanavir—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0292	0.0595	CbGbCtD
Atazanavir—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.028	0.057	CbGbCtD
Atazanavir—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0203	0.0412	CbGbCtD
Atazanavir—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0175	0.0357	CbGbCtD
Atazanavir—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0163	0.0331	CbGbCtD
Atazanavir—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0125	0.0254	CbGbCtD
Atazanavir—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.012	0.0244	CbGbCtD
Atazanavir—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0116	0.0237	CbGbCtD
Atazanavir—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0114	0.0233	CbGbCtD
Atazanavir—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.0078	0.0159	CbGbCtD
Atazanavir—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.00748	0.0152	CbGbCtD
Atazanavir—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.00685	0.0139	CbGbCtD
Atazanavir—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00467	0.00951	CbGbCtD
Atazanavir—Lopinavir—ABCB1—peripheral nervous system neoplasm	0.000748	0.404	CrCbGaD
Atazanavir—Ritonavir—ABCB1—peripheral nervous system neoplasm	0.000629	0.339	CrCbGaD
Atazanavir—Saquinavir—ABCB1—peripheral nervous system neoplasm	0.000477	0.257	CrCbGaD
Atazanavir—Infection—Etoposide—peripheral nervous system neoplasm	8.79e-05	0.000462	CcSEcCtD
Atazanavir—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	8.78e-05	0.000462	CcSEcCtD
Atazanavir—Asthenia—Dactinomycin—peripheral nervous system neoplasm	8.77e-05	0.000461	CcSEcCtD
Atazanavir—Nausea—Melphalan—peripheral nervous system neoplasm	8.77e-05	0.000461	CcSEcCtD
Atazanavir—Dehydration—Doxorubicin—peripheral nervous system neoplasm	8.68e-05	0.000457	CcSEcCtD
Atazanavir—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	8.63e-05	0.000454	CcSEcCtD
Atazanavir—Body temperature increased—Vincristine—peripheral nervous system neoplasm	8.63e-05	0.000454	CcSEcCtD
Atazanavir—Abdominal pain—Vincristine—peripheral nervous system neoplasm	8.63e-05	0.000454	CcSEcCtD
Atazanavir—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	8.61e-05	0.000453	CcSEcCtD
Atazanavir—Skin disorder—Etoposide—peripheral nervous system neoplasm	8.59e-05	0.000452	CcSEcCtD
Atazanavir—Dry skin—Doxorubicin—peripheral nervous system neoplasm	8.55e-05	0.00045	CcSEcCtD
Atazanavir—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	8.55e-05	0.00045	CcSEcCtD
Atazanavir—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	8.55e-05	0.00045	CcSEcCtD
Atazanavir—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	8.43e-05	0.000444	CcSEcCtD
Atazanavir—Anorexia—Etoposide—peripheral nervous system neoplasm	8.43e-05	0.000444	CcSEcCtD
Atazanavir—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	8.4e-05	0.000442	CcSEcCtD
Atazanavir—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	8.39e-05	0.000442	CcSEcCtD
Atazanavir—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	8.36e-05	0.00044	CcSEcCtD
Atazanavir—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	8.35e-05	0.000439	CcSEcCtD
Atazanavir—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	8.35e-05	0.000439	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	8.33e-05	0.000439	CcSEcCtD
Atazanavir—Gastritis—Doxorubicin—peripheral nervous system neoplasm	8.26e-05	0.000435	CcSEcCtD
Atazanavir—Pain—Cisplatin—peripheral nervous system neoplasm	8.26e-05	0.000434	CcSEcCtD
Atazanavir—Muscular weakness—Doxorubicin—peripheral nervous system neoplasm	8.23e-05	0.000433	CcSEcCtD
Atazanavir—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	8.23e-05	0.000433	CcSEcCtD
Atazanavir—Neutropenia—Epirubicin—peripheral nervous system neoplasm	8.15e-05	0.000429	CcSEcCtD
Atazanavir—Asthenia—Alitretinoin—peripheral nervous system neoplasm	8.13e-05	0.000428	CcSEcCtD
Atazanavir—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	8.12e-05	0.000427	CcSEcCtD
Atazanavir—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	8.05e-05	0.000424	CcSEcCtD
Atazanavir—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	8.04e-05	0.000423	CcSEcCtD
Atazanavir—Pruritus—Alitretinoin—peripheral nervous system neoplasm	8.02e-05	0.000422	CcSEcCtD
Atazanavir—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	7.99e-05	0.00042	CcSEcCtD
Atazanavir—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	7.96e-05	0.000419	CcSEcCtD
Atazanavir—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	7.96e-05	0.000419	CcSEcCtD
Atazanavir—Weight increased—Epirubicin—peripheral nervous system neoplasm	7.93e-05	0.000418	CcSEcCtD
Atazanavir—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	7.91e-05	0.000416	CcSEcCtD
Atazanavir—Weight decreased—Epirubicin—peripheral nervous system neoplasm	7.89e-05	0.000415	CcSEcCtD
Atazanavir—Dyspnoea—Etoposide—peripheral nervous system neoplasm	7.88e-05	0.000415	CcSEcCtD
Atazanavir—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	7.86e-05	0.000414	CcSEcCtD
Atazanavir—Somnolence—Etoposide—peripheral nervous system neoplasm	7.86e-05	0.000414	CcSEcCtD
Atazanavir—Asthenia—Vincristine—peripheral nervous system neoplasm	7.83e-05	0.000412	CcSEcCtD
Atazanavir—Vomiting—Dactinomycin—peripheral nervous system neoplasm	7.77e-05	0.000409	CcSEcCtD
Atazanavir—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	7.75e-05	0.000408	CcSEcCtD
Atazanavir—Stevens-Johnson syndrome—Epirubicin—peripheral nervous system neoplasm	7.71e-05	0.000406	CcSEcCtD
Atazanavir—Rash—Dactinomycin—peripheral nervous system neoplasm	7.7e-05	0.000405	CcSEcCtD
Atazanavir—Decreased appetite—Etoposide—peripheral nervous system neoplasm	7.69e-05	0.000405	CcSEcCtD
Atazanavir—Renal failure—Epirubicin—peripheral nervous system neoplasm	7.64e-05	0.000402	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	7.64e-05	0.000402	CcSEcCtD
Atazanavir—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	7.63e-05	0.000402	CcSEcCtD
Atazanavir—Fatigue—Etoposide—peripheral nervous system neoplasm	7.63e-05	0.000401	CcSEcCtD
Atazanavir—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	7.62e-05	0.000401	CcSEcCtD
Atazanavir—Jaundice—Epirubicin—peripheral nervous system neoplasm	7.58e-05	0.000399	CcSEcCtD
Atazanavir—Stomatitis—Epirubicin—peripheral nervous system neoplasm	7.58e-05	0.000399	CcSEcCtD
Atazanavir—Pain—Etoposide—peripheral nervous system neoplasm	7.56e-05	0.000398	CcSEcCtD
Atazanavir—Constipation—Etoposide—peripheral nervous system neoplasm	7.56e-05	0.000398	CcSEcCtD
Atazanavir—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	7.56e-05	0.000398	CcSEcCtD
Atazanavir—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	7.54e-05	0.000397	CcSEcCtD
Atazanavir—Dizziness—Alitretinoin—peripheral nervous system neoplasm	7.49e-05	0.000394	CcSEcCtD
Atazanavir—Diarrhoea—Vincristine—peripheral nervous system neoplasm	7.47e-05	0.000393	CcSEcCtD
Atazanavir—Sweating—Epirubicin—peripheral nervous system neoplasm	7.45e-05	0.000392	CcSEcCtD
Atazanavir—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	7.45e-05	0.000392	CcSEcCtD
Atazanavir—Haematuria—Epirubicin—peripheral nervous system neoplasm	7.41e-05	0.00039	CcSEcCtD
Atazanavir—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	7.36e-05	0.000387	CcSEcCtD
Atazanavir—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	7.35e-05	0.000387	CcSEcCtD
Atazanavir—Weight increased—Doxorubicin—peripheral nervous system neoplasm	7.34e-05	0.000386	CcSEcCtD
Atazanavir—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	7.3e-05	0.000384	CcSEcCtD
Atazanavir—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	7.29e-05	0.000384	CcSEcCtD
Atazanavir—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	7.28e-05	0.000383	CcSEcCtD
Atazanavir—Nausea—Dactinomycin—peripheral nervous system neoplasm	7.26e-05	0.000382	CcSEcCtD
Atazanavir—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	7.23e-05	0.000381	CcSEcCtD
Atazanavir—Dizziness—Vincristine—peripheral nervous system neoplasm	7.22e-05	0.00038	CcSEcCtD
Atazanavir—Vomiting—Alitretinoin—peripheral nervous system neoplasm	7.2e-05	0.000379	CcSEcCtD
Atazanavir—Rash—Alitretinoin—peripheral nervous system neoplasm	7.14e-05	0.000376	CcSEcCtD
Atazanavir—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	7.14e-05	0.000376	CcSEcCtD
Atazanavir—Stevens-Johnson syndrome—Doxorubicin—peripheral nervous system neoplasm	7.13e-05	0.000375	CcSEcCtD
Atazanavir—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	7.11e-05	0.000374	CcSEcCtD
Atazanavir—Headache—Alitretinoin—peripheral nervous system neoplasm	7.1e-05	0.000374	CcSEcCtD
Atazanavir—Renal failure—Doxorubicin—peripheral nervous system neoplasm	7.07e-05	0.000372	CcSEcCtD
Atazanavir—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	7.05e-05	0.000371	CcSEcCtD
Atazanavir—Urticaria—Etoposide—peripheral nervous system neoplasm	7.03e-05	0.00037	CcSEcCtD
Atazanavir—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	7.01e-05	0.000369	CcSEcCtD
Atazanavir—Jaundice—Doxorubicin—peripheral nervous system neoplasm	7.01e-05	0.000369	CcSEcCtD
Atazanavir—Abdominal pain—Etoposide—peripheral nervous system neoplasm	6.99e-05	0.000368	CcSEcCtD
Atazanavir—Body temperature increased—Etoposide—peripheral nervous system neoplasm	6.99e-05	0.000368	CcSEcCtD
Atazanavir—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	6.99e-05	0.000368	CcSEcCtD
Atazanavir—Hepatitis—Epirubicin—peripheral nervous system neoplasm	6.98e-05	0.000367	CcSEcCtD
Atazanavir—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	6.94e-05	0.000365	CcSEcCtD
Atazanavir—Vomiting—Vincristine—peripheral nervous system neoplasm	6.94e-05	0.000365	CcSEcCtD
Atazanavir—Asthenia—Cisplatin—peripheral nervous system neoplasm	6.93e-05	0.000365	CcSEcCtD
Atazanavir—Sweating—Doxorubicin—peripheral nervous system neoplasm	6.9e-05	0.000363	CcSEcCtD
Atazanavir—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	6.89e-05	0.000363	CcSEcCtD
Atazanavir—Rash—Vincristine—peripheral nervous system neoplasm	6.88e-05	0.000362	CcSEcCtD
Atazanavir—Dermatitis—Vincristine—peripheral nervous system neoplasm	6.88e-05	0.000362	CcSEcCtD
Atazanavir—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	6.87e-05	0.000362	CcSEcCtD
Atazanavir—Haematuria—Doxorubicin—peripheral nervous system neoplasm	6.86e-05	0.000361	CcSEcCtD
Atazanavir—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	6.86e-05	0.000361	CcSEcCtD
Atazanavir—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	6.84e-05	0.00036	CcSEcCtD
Atazanavir—Headache—Vincristine—peripheral nervous system neoplasm	6.84e-05	0.00036	CcSEcCtD
Atazanavir—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	6.8e-05	0.000358	CcSEcCtD
Atazanavir—Nausea—Alitretinoin—peripheral nervous system neoplasm	6.73e-05	0.000354	CcSEcCtD
Atazanavir—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	6.61e-05	0.000348	CcSEcCtD
Atazanavir—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	6.6e-05	0.000347	CcSEcCtD
Atazanavir—Eye disorder—Epirubicin—peripheral nervous system neoplasm	6.52e-05	0.000343	CcSEcCtD
Atazanavir—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	6.52e-05	0.000343	CcSEcCtD
Atazanavir—Tinnitus—Epirubicin—peripheral nervous system neoplasm	6.51e-05	0.000342	CcSEcCtD
Atazanavir—Nausea—Vincristine—peripheral nervous system neoplasm	6.49e-05	0.000341	CcSEcCtD
Atazanavir—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	6.48e-05	0.000341	CcSEcCtD
Atazanavir—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	6.46e-05	0.00034	CcSEcCtD
Atazanavir—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	6.42e-05	0.000338	CcSEcCtD
Atazanavir—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	6.38e-05	0.000336	CcSEcCtD
Atazanavir—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	6.36e-05	0.000335	CcSEcCtD
Atazanavir—Asthenia—Etoposide—peripheral nervous system neoplasm	6.35e-05	0.000334	CcSEcCtD
Atazanavir—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	6.34e-05	0.000334	CcSEcCtD
Atazanavir—Angiopathy—Epirubicin—peripheral nervous system neoplasm	6.33e-05	0.000333	CcSEcCtD
Atazanavir—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	6.33e-05	0.000333	CcSEcCtD
Atazanavir—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	6.3e-05	0.000332	CcSEcCtD
Atazanavir—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	6.29e-05	0.000331	CcSEcCtD
Atazanavir—Pruritus—Etoposide—peripheral nervous system neoplasm	6.26e-05	0.000329	CcSEcCtD
Atazanavir—Alopecia—Epirubicin—peripheral nervous system neoplasm	6.17e-05	0.000325	CcSEcCtD
Atazanavir—Vomiting—Cisplatin—peripheral nervous system neoplasm	6.14e-05	0.000323	CcSEcCtD
Atazanavir—Mental disorder—Epirubicin—peripheral nervous system neoplasm	6.11e-05	0.000322	CcSEcCtD
Atazanavir—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	6.1e-05	0.000321	CcSEcCtD
Atazanavir—Rash—Cisplatin—peripheral nervous system neoplasm	6.09e-05	0.00032	CcSEcCtD
Atazanavir—Dermatitis—Cisplatin—peripheral nervous system neoplasm	6.08e-05	0.00032	CcSEcCtD
Atazanavir—Malnutrition—Epirubicin—peripheral nervous system neoplasm	6.07e-05	0.00032	CcSEcCtD
Atazanavir—Diarrhoea—Etoposide—peripheral nervous system neoplasm	6.05e-05	0.000318	CcSEcCtD
Atazanavir—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	6.03e-05	0.000318	CcSEcCtD
Atazanavir—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	6.02e-05	0.000317	CcSEcCtD
Atazanavir—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	5.99e-05	0.000315	CcSEcCtD
Atazanavir—Flatulence—Epirubicin—peripheral nervous system neoplasm	5.99e-05	0.000315	CcSEcCtD
Atazanavir—Tension—Epirubicin—peripheral nervous system neoplasm	5.96e-05	0.000314	CcSEcCtD
Atazanavir—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	5.95e-05	0.000313	CcSEcCtD
Atazanavir—Nervousness—Epirubicin—peripheral nervous system neoplasm	5.9e-05	0.00031	CcSEcCtD
Atazanavir—Back pain—Epirubicin—peripheral nervous system neoplasm	5.88e-05	0.000309	CcSEcCtD
Atazanavir—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	5.86e-05	0.000308	CcSEcCtD
Atazanavir—Dizziness—Etoposide—peripheral nervous system neoplasm	5.85e-05	0.000308	CcSEcCtD
Atazanavir—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	5.83e-05	0.000307	CcSEcCtD
Atazanavir—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	5.82e-05	0.000306	CcSEcCtD
Atazanavir—Nausea—Cisplatin—peripheral nervous system neoplasm	5.73e-05	0.000302	CcSEcCtD
Atazanavir—Alopecia—Doxorubicin—peripheral nervous system neoplasm	5.71e-05	0.0003	CcSEcCtD
Atazanavir—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	5.66e-05	0.000298	CcSEcCtD
Atazanavir—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	5.64e-05	0.000297	CcSEcCtD
Atazanavir—Vomiting—Etoposide—peripheral nervous system neoplasm	5.62e-05	0.000296	CcSEcCtD
Atazanavir—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	5.62e-05	0.000296	CcSEcCtD
Atazanavir—Agitation—Epirubicin—peripheral nervous system neoplasm	5.58e-05	0.000294	CcSEcCtD
Atazanavir—Rash—Etoposide—peripheral nervous system neoplasm	5.58e-05	0.000293	CcSEcCtD
Atazanavir—Dermatitis—Etoposide—peripheral nervous system neoplasm	5.57e-05	0.000293	CcSEcCtD
Atazanavir—Headache—Etoposide—peripheral nervous system neoplasm	5.54e-05	0.000292	CcSEcCtD
Atazanavir—Flatulence—Doxorubicin—peripheral nervous system neoplasm	5.54e-05	0.000291	CcSEcCtD
Atazanavir—Tension—Doxorubicin—peripheral nervous system neoplasm	5.52e-05	0.00029	CcSEcCtD
Atazanavir—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	5.5e-05	0.00029	CcSEcCtD
Atazanavir—Malaise—Epirubicin—peripheral nervous system neoplasm	5.48e-05	0.000288	CcSEcCtD
Atazanavir—Nervousness—Doxorubicin—peripheral nervous system neoplasm	5.46e-05	0.000287	CcSEcCtD
Atazanavir—Syncope—Epirubicin—peripheral nervous system neoplasm	5.45e-05	0.000287	CcSEcCtD
Atazanavir—Back pain—Doxorubicin—peripheral nervous system neoplasm	5.44e-05	0.000286	CcSEcCtD
Atazanavir—Palpitations—Epirubicin—peripheral nervous system neoplasm	5.37e-05	0.000283	CcSEcCtD
Atazanavir—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	5.34e-05	0.000281	CcSEcCtD
Atazanavir—Cough—Epirubicin—peripheral nervous system neoplasm	5.3e-05	0.000279	CcSEcCtD
Atazanavir—Convulsion—Epirubicin—peripheral nervous system neoplasm	5.26e-05	0.000277	CcSEcCtD
Atazanavir—Nausea—Etoposide—peripheral nervous system neoplasm	5.25e-05	0.000276	CcSEcCtD
Atazanavir—Hypertension—Epirubicin—peripheral nervous system neoplasm	5.24e-05	0.000276	CcSEcCtD
Atazanavir—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	5.22e-05	0.000274	CcSEcCtD
Atazanavir—Chest pain—Epirubicin—peripheral nervous system neoplasm	5.17e-05	0.000272	CcSEcCtD
Atazanavir—Arthralgia—Epirubicin—peripheral nervous system neoplasm	5.17e-05	0.000272	CcSEcCtD
Atazanavir—Myalgia—Epirubicin—peripheral nervous system neoplasm	5.17e-05	0.000272	CcSEcCtD
Atazanavir—Agitation—Doxorubicin—peripheral nervous system neoplasm	5.17e-05	0.000272	CcSEcCtD
Atazanavir—Anxiety—Epirubicin—peripheral nervous system neoplasm	5.15e-05	0.000271	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	5.14e-05	0.00027	CcSEcCtD
Atazanavir—Discomfort—Epirubicin—peripheral nervous system neoplasm	5.11e-05	0.000269	CcSEcCtD
Atazanavir—Malaise—Doxorubicin—peripheral nervous system neoplasm	5.07e-05	0.000267	CcSEcCtD
Atazanavir—Dry mouth—Epirubicin—peripheral nervous system neoplasm	5.06e-05	0.000266	CcSEcCtD
Atazanavir—Syncope—Doxorubicin—peripheral nervous system neoplasm	5.04e-05	0.000265	CcSEcCtD
Atazanavir—Confusional state—Epirubicin—peripheral nervous system neoplasm	5e-05	0.000263	CcSEcCtD
Atazanavir—Palpitations—Doxorubicin—peripheral nervous system neoplasm	4.97e-05	0.000261	CcSEcCtD
Atazanavir—Oedema—Epirubicin—peripheral nervous system neoplasm	4.96e-05	0.000261	CcSEcCtD
Atazanavir—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	4.94e-05	0.00026	CcSEcCtD
Atazanavir—Infection—Epirubicin—peripheral nervous system neoplasm	4.93e-05	0.000259	CcSEcCtD
Atazanavir—Cough—Doxorubicin—peripheral nervous system neoplasm	4.9e-05	0.000258	CcSEcCtD
Atazanavir—Shock—Epirubicin—peripheral nervous system neoplasm	4.88e-05	0.000257	CcSEcCtD
Atazanavir—Convulsion—Doxorubicin—peripheral nervous system neoplasm	4.87e-05	0.000256	CcSEcCtD
Atazanavir—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	4.86e-05	0.000256	CcSEcCtD
Atazanavir—Hypertension—Doxorubicin—peripheral nervous system neoplasm	4.85e-05	0.000255	CcSEcCtD
Atazanavir—Skin disorder—Epirubicin—peripheral nervous system neoplasm	4.82e-05	0.000253	CcSEcCtD
Atazanavir—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	4.79e-05	0.000252	CcSEcCtD
Atazanavir—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	4.79e-05	0.000252	CcSEcCtD
Atazanavir—Chest pain—Doxorubicin—peripheral nervous system neoplasm	4.79e-05	0.000252	CcSEcCtD
Atazanavir—Myalgia—Doxorubicin—peripheral nervous system neoplasm	4.79e-05	0.000252	CcSEcCtD
Atazanavir—Anxiety—Doxorubicin—peripheral nervous system neoplasm	4.77e-05	0.000251	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	4.75e-05	0.00025	CcSEcCtD
Atazanavir—Discomfort—Doxorubicin—peripheral nervous system neoplasm	4.73e-05	0.000249	CcSEcCtD
Atazanavir—Anorexia—Epirubicin—peripheral nervous system neoplasm	4.73e-05	0.000249	CcSEcCtD
Atazanavir—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	4.68e-05	0.000246	CcSEcCtD
Atazanavir—Confusional state—Doxorubicin—peripheral nervous system neoplasm	4.63e-05	0.000243	CcSEcCtD
Atazanavir—Oedema—Doxorubicin—peripheral nervous system neoplasm	4.59e-05	0.000241	CcSEcCtD
Atazanavir—Infection—Doxorubicin—peripheral nervous system neoplasm	4.56e-05	0.00024	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	4.52e-05	0.000238	CcSEcCtD
Atazanavir—Shock—Doxorubicin—peripheral nervous system neoplasm	4.51e-05	0.000238	CcSEcCtD
Atazanavir—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	4.5e-05	0.000237	CcSEcCtD
Atazanavir—Insomnia—Epirubicin—peripheral nervous system neoplasm	4.48e-05	0.000236	CcSEcCtD
Atazanavir—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	4.46e-05	0.000234	CcSEcCtD
Atazanavir—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	4.43e-05	0.000233	CcSEcCtD
Atazanavir—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	4.42e-05	0.000233	CcSEcCtD
Atazanavir—Somnolence—Epirubicin—peripheral nervous system neoplasm	4.41e-05	0.000232	CcSEcCtD
Atazanavir—Anorexia—Doxorubicin—peripheral nervous system neoplasm	4.37e-05	0.00023	CcSEcCtD
Atazanavir—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	4.36e-05	0.00023	CcSEcCtD
Atazanavir—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	4.31e-05	0.000227	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	4.28e-05	0.000225	CcSEcCtD
Atazanavir—Fatigue—Epirubicin—peripheral nervous system neoplasm	4.27e-05	0.000225	CcSEcCtD
Atazanavir—Constipation—Epirubicin—peripheral nervous system neoplasm	4.24e-05	0.000223	CcSEcCtD
Atazanavir—Pain—Epirubicin—peripheral nervous system neoplasm	4.24e-05	0.000223	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	4.18e-05	0.00022	CcSEcCtD
Atazanavir—Insomnia—Doxorubicin—peripheral nervous system neoplasm	4.15e-05	0.000218	CcSEcCtD
Atazanavir—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	4.09e-05	0.000215	CcSEcCtD
Atazanavir—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	4.09e-05	0.000215	CcSEcCtD
Atazanavir—Somnolence—Doxorubicin—peripheral nervous system neoplasm	4.08e-05	0.000215	CcSEcCtD
Atazanavir—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	4.05e-05	0.000213	CcSEcCtD
Atazanavir—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	4.04e-05	0.000213	CcSEcCtD
Atazanavir—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	3.99e-05	0.00021	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.96e-05	0.000208	CcSEcCtD
Atazanavir—Fatigue—Doxorubicin—peripheral nervous system neoplasm	3.95e-05	0.000208	CcSEcCtD
Atazanavir—Urticaria—Epirubicin—peripheral nervous system neoplasm	3.94e-05	0.000207	CcSEcCtD
Atazanavir—Pain—Doxorubicin—peripheral nervous system neoplasm	3.92e-05	0.000206	CcSEcCtD
Atazanavir—Constipation—Doxorubicin—peripheral nervous system neoplasm	3.92e-05	0.000206	CcSEcCtD
Atazanavir—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	3.92e-05	0.000206	CcSEcCtD
Atazanavir—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	3.92e-05	0.000206	CcSEcCtD
Atazanavir—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	3.78e-05	0.000199	CcSEcCtD
Atazanavir—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	3.75e-05	0.000197	CcSEcCtD
Atazanavir—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	3.65e-05	0.000192	CcSEcCtD
Atazanavir—Urticaria—Doxorubicin—peripheral nervous system neoplasm	3.64e-05	0.000192	CcSEcCtD
Atazanavir—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	3.63e-05	0.000191	CcSEcCtD
Atazanavir—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	3.63e-05	0.000191	CcSEcCtD
Atazanavir—Asthenia—Epirubicin—peripheral nervous system neoplasm	3.56e-05	0.000187	CcSEcCtD
Atazanavir—Pruritus—Epirubicin—peripheral nervous system neoplasm	3.51e-05	0.000185	CcSEcCtD
Atazanavir—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	3.39e-05	0.000179	CcSEcCtD
Atazanavir—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	3.38e-05	0.000178	CcSEcCtD
Atazanavir—Asthenia—Doxorubicin—peripheral nervous system neoplasm	3.29e-05	0.000173	CcSEcCtD
Atazanavir—Dizziness—Epirubicin—peripheral nervous system neoplasm	3.28e-05	0.000173	CcSEcCtD
Atazanavir—Pruritus—Doxorubicin—peripheral nervous system neoplasm	3.25e-05	0.000171	CcSEcCtD
Atazanavir—Vomiting—Epirubicin—peripheral nervous system neoplasm	3.15e-05	0.000166	CcSEcCtD
Atazanavir—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	3.14e-05	0.000165	CcSEcCtD
Atazanavir—Rash—Epirubicin—peripheral nervous system neoplasm	3.13e-05	0.000165	CcSEcCtD
Atazanavir—Dermatitis—Epirubicin—peripheral nervous system neoplasm	3.12e-05	0.000164	CcSEcCtD
Atazanavir—Headache—Epirubicin—peripheral nervous system neoplasm	3.11e-05	0.000163	CcSEcCtD
Atazanavir—Dizziness—Doxorubicin—peripheral nervous system neoplasm	3.03e-05	0.00016	CcSEcCtD
Atazanavir—Nausea—Epirubicin—peripheral nervous system neoplasm	2.94e-05	0.000155	CcSEcCtD
Atazanavir—Vomiting—Doxorubicin—peripheral nervous system neoplasm	2.92e-05	0.000153	CcSEcCtD
Atazanavir—Rash—Doxorubicin—peripheral nervous system neoplasm	2.89e-05	0.000152	CcSEcCtD
Atazanavir—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.89e-05	0.000152	CcSEcCtD
Atazanavir—Headache—Doxorubicin—peripheral nervous system neoplasm	2.87e-05	0.000151	CcSEcCtD
Atazanavir—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.72e-05	0.000143	CcSEcCtD
